Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217587 · ClinicalTrials.gov registry record · Phase 3
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
A Phase 3 study of Myasthenia Gravis, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
- 7
- Study locations
NCT07217587: Recruiting Phase 3 study of Myasthenia Gravis, sponsored by Janssen Research & Development.
NCT07217587 is a Phase 3 study of Myasthenia Gravis that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 115 participants, below the 188-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (39% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217587, a Phase 3 study of Myasthenia Gravis, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
Primary Outcome
Average mean percent change from baseline in total IgG levels over Weeks 8 , 10 and 12 will be reported.
Conditions Studied
Interventions
- DRUG Nipocalimab
- DRUG Efgartigimod
Study Locations (7)
Other
- Rambam Medical Center - Haifa
- Sourasky Medical Center - Tel Aviv
Connecticut
- University of Connecticut - Farmington
Florida
- SFM Clinical Research LLC - Boca Raton
Illinois
- HSHS St. Elizabeth's Hospital - O'Fallon
Michigan
- Henry Ford Hospital - Detroit
North Carolina
- Atrium Health Wake Forest Baptist - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2028-12-11 |
| Phase | Phase 3 |
What NCT07217587 shows while recruiting
NCT07217587 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 188-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Nipocalimab is the first listed.
NCT07217587 lists 7 locations in 6 states (Other, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT07217587 about?
NCT07217587 is a clinical study titled "Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis". The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
What is the current status of trial NCT07217587?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2026-01-05. Estimated completion is 2028-12-11.
What conditions does trial NCT07217587 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT07217587?
The interventions under investigation include: Nipocalimab (DRUG), Efgartigimod (DRUG).
Who is sponsoring clinical trial NCT07217587?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217587 being conducted?
This trial has 7 study locations across Connecticut, Florida, Illinois, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07217587's enrollment target sits among peer trials
115 15th of 32 higher than 18 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Myasthenia Gravis Inebilizumab Trial
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
-
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
COMPLETED · Phase 3
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI